The ATG2B Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for targeted disruption of the human ATG2B gene in an A-549 host cell background. This product provides a loss-of-function model for investigating the autophagy-related roles of ATG2B, a lipid transfer protein essential for autophagosome biogenesis. The polyclonal knockout population offers a genetically heterogeneous pool of A-549 cells with CRISPR/Cas9-mediated gene disruption, enabling robust assessment of ATG2B-dependent processes. As with all products, the exact editing outcome and knockout efficiency are not specified, and the cells are not guaranteed to be monoclonal or biallelic. Researchers should expect a mixed population of edited alleles that collectively abolish ATG2B function.
The host A-549 cell line is a well-characterized human lung adenocarcinoma epithelial model derived from tumor tissue, exhibiting adherent morphology and retaining features such as surfactant protein expression. These cells carry a KRAS G12S activating mutation and are null for the tumor suppressor STK11, a genetic context frequently observed in lung adenocarcinoma. The combination of oncogenic KRAS signaling and loss of STK11 creates a permissive background for studying autophagy modulation and its impact on tumor cell survival, metabolism, and therapy response. A-549 cells are widely employed in cancer biology, and their adherent growth and ease of manipulation make them suitable for a range of functional assays.
ATG2B functions as a lipid transfer protein that bridges the endoplasmic reticulum and the nascent phagophore by interacting with WIPI family proteins, notably WIPI2 and WIPI4, at omegasome structures. Through this interaction, ATG2B facilitates the delivery of phospholipids required for phagophore membrane expansion, a rate-limiting step in autophagosome formation. The protein is subject to negative regulation by mTORC1 and positive regulation by AMPK, both acting upstream through the ULK1 complex. Downstream, ATG2B activity promotes the lipidation of LC3-I to LC3-II and the degradation of the adaptor protein p62/SQSTM1, hallmarks of autophagic flux. Additional interacting partners include ATG9A, which contributes to membrane recruitment, and LC3 itself. Representative pathway components span from the mTORC1-AMPK-ULK1 axis to the PI3K complex containing VPS34 and Beclin-1, the ATG2B-WIPI complex, and the final conjugation of LC3-II to the phagophore.
In the A-549 lung adenocarcinoma context, ATG2B knockout provides a specific means to dismantle autophagy, a process often upregulated in cancer cells to sustain survival under metabolic or therapeutic stress. The KRAS/STK11 mutational profile is associated with heightened autophagic dependence, making this knockout model particularly relevant for dissecting autophagy’s contribution to tumor maintenance and drug resistance. Disruption of ATG2B is expected to impair autophagosome biogenesis, leading to attenuated autophagic flux and potential sensitization to starvation or chemotherapeutic agents such as cisplatin. By studying these cells, researchers can delineate how lipid transfer at omegasomes influences lung cancer cell fate, migration, and invasion, and whether targeting ATG2B represents a vulnerability in certain genetic backgrounds.
This polyclonal knockout product is suited for a broad spectrum of research applications, including autophagy research, cancer biology, drug resistance studies, and high-throughput screening of autophagy modulators. Typical experimental approaches include Western blotting for LC3-II and p62 to monitor autophagic markers, autophagic flux assays using chloroquine or bafilomycin A1, immunofluorescence microscopy to visualize LC3 puncta, and electron microscopy for ultrastructural analysis of autophagosomes. The model also supports cell viability assays under nutrient-depleted conditions, migration and invasion tests, and drug sensitivity profiling with agents such as cisplatin. For additional information or technical support, please contact Ascent Research.
